Investors & Media

We are driven to develop meaningful therapies for patients while creating value for stockholders.

Investors & Media

Corporate Profile

We are a biopharmaceutical company on a mission to develop treatments for serious diseases.

Press Releases

Aug 07, 2024

Regina Graul, Ph.D., Promoted to Chief Executive Officer

Dec 04, 2023

Cyclerion Appoints Regina Graul, Ph.D., as President

Nov 30, 2023

Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator

Jul 31, 2023

Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets

view all

Stock Quote

Change
Volume
52 Week High
52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Top